ARHGEF16

Across TCGA pan-cancer cohorts, ARHGEF16 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ARHGEF16’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ARHGEF16 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGEF16 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

LUAD, PDAC, and LSCC are the cancer types where ARHGEF16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	+0.779	<.001	9	view →
PDAC	All	III,IV	+0.612	.001	9	view →
LSCC	Female	II,III,IV	+0.723	<.001	8	view →
HNSC	All	All	−0.209	.007	8	view →
CCRCC	Male	All	+0.255	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ARHGEF16–LUAD

Open the LUAD breakdown →